Provectus Biopharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Provectus Biopharmaceuticals announces its 2026 Annual Meeting of Stockholders on June 18, 2026, and proposes a reverse stock split to increase its common stock's marketability.
OQB
Provectus Biopharmaceuticals, Inc. has announced that its 2025 annual stockholder meeting will be held on June 18, 2025, in Knoxville, Tennessee, with an option for virtual attendance via Zoom Webinar.
OQB
Provectus Biopharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.
OQB
DEF 14A: Provectus Biopharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Share Reduction
Provectus Biopharmaceuticals is asking stockholders to approve a reverse stock split and a corresponding reduction in the number of authorized shares to improve marketability and align share structure.
OQB
DEFA14A: Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Stockholder Meeting
Provectus Biopharmaceuticals will hold its 2024 annual stockholder meeting, including a company update, accessible via Zoom Webinar on June 20, 2024.
OQB
Provectus Biopharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.
OQB
Provectus Biopharmaceuticals is asking stockholders to approve a reverse stock split, a decrease in authorized shares, and a new equity compensation plan at its upcoming annual meeting.